Yazar "Karandere, Faruk" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Association of Hypophosphatemia with Morbidity and Mortality in Patients with COVID-19
    (Alanya Alaaddin Keykubat Üniversitesi, 2023) Karandere, Faruk; Yılmaz, Deniz; Arslan, Felemez; Şahin, Ezgi; Koyuncu, Sema
    Aim: In critical cases, electrolyte disturbances such as hypophosphatemia have been shown to be associated with mortality and in our study, we aimed to examine the relationship between hypophosphatemia, a symptom disorder with COVID-19, and death. Material and Methods: This study is a retrospective, cross-sectional investigation that encompasses patients diagnosed with COVID-19 and subsequently admitted for treatment at our hospital. Based on their serum phosphate levels, the patients were bifurcated into two distinct categories: those with serum phosphate levels below 2.5 mg/dl, classified as hypophosphatemic, and those with levels above this benchmark, categorized as non-hypophosphatemic. The comparisons drawn between these two cohorts were facilitated using a range of statistical methodologies, and the resulting findings were subsequently analyzed and interpreted within this framework. Results: Compared to the hypophosphatemia group, the diagnoses of DM (p<0.001) and CKD (p=0.015) were statistically significantly higher in the group without hypophosphatemia. A statistically significant difference was found between phosphorus groups and mortality and length of stay (p<0.001). In addition, age and length of hospitalization were found to be statistically significantly higher in those who died compared to those who were alive (p<0.001; p=0.002). Conclusions: Hypophosphatemia has been shown to be associated with mortality in patients with COVID-19, as in many studies and in our study, and it may be a biomarker in predicting severe disease.
  • [ X ]
    Öğe
    Covid 19'a Bağlı Hiperinflamasyonda Tocilizumab Tedavisinin Serokonversiyon Üzerine Etkisi
    (Alanya Alaaddin Keykubat Üniversitesi, 2024) Karandere, Faruk; Yılmaz, Deniz; Arslan, Felemez; Şahin, Ezgi; Koçoğlu, Hakan; Işıksaçan, Nilgün
    Amaç:Devam eden COVID-19 pandemisi sürecinde, hastalığa ikincil olarak ortaya çıkan ciddi bir semptom olan hiperinflamasyonun yönetimi büyük bir meydan okuma olarak karşımıza çıkmıştır. İmmünsüpresif bir ilaç olan Tocilizumab, potansiyel bir çözüm sunmaktadır. Ancak, Covid-19'dan iyileşme sonrası antikor oluşumu üzerindeki etkilerini anlamak son derece önemlidir. Bu nedenle, çalışmamız bu spesifik tedaviyi alan hastalarda, enfeksiyon sonrası üçüncü ayda SARS-COV-2 spike toplam antikor seviyelerini ölçerek, tocilizumab tedavisinin antikor üretimi üzerindeki etkilerini araştırmayı amaçlamıştır. Yöntemler: Çalışmamız, hastaneye yatırıldıkları sırada hiperinflamasyon gösteren ve Covid-19 tanısı almış 48 hastayı içermektedir. Bu hastalar kurumumuza kabul edilmiş, tocilizumab ile tedavi edilmiş ve sonrasında taburcu edilmişlerdir. Bu hastaların 3. ay SARS-COV-2 spike toplam antikor seviyeleri titizlikle belirlenmiştir. Bulgular: Çalışmanın katılımcıları, ortalama yaşları 52,5 ± 11,6 olan, yaş, cinsiyet, komorbidite ve hastanede kalış süresi ne olursa olsun 3. ayda pozitif SARS-COV-2 spike toplam antikor seviyeleri göstermiştir. Hastaların ortalama antikor seviyeleri 223,58 ± 68,36 U/mL olarak ölçülmüş, aralık 14,2 ile 250 U/mL arasında değişmiştir. Sonuç: Bulgularımız, tüm hastaların tocilizumab tedavisi sonrası 3 ayda pozitif antikor seviyeleri sergilediklerini ortaya koymaktadır. Bu, hiperinflamasyonun Covid 19'a ikincil yönetiminde tocilizumab uygulamasının, en azından kısa vadede, antikor oluşumunu olumsuz etkilemediğini göstermektedir. Bu, gelecekteki tedavi stratejileri için önemli sonuçlar doğurabilir.
  • [ X ]
    Öğe
    Predictors of anxiety, depression and health anxiety in COVID-19 infected patients with lung involvement in inpatient units
    (Bayrakol Medical Publisher, 2022) Karandere, Faruk; Kuru, Tacettin; Kara, Tayfun
    Aim: Although numerous community-based studies and case reports have been published on COVID-19 and its psychological effects, studies involving hospitalized patients are limited. The purpose of the present study was to evaluate indicators associated with anxiety, depression, and health anxiety in patients with COVID-19 pneumonia. Material and Methods: One hundred ninety-eight patients hospitalized with diagnoses of COVID-19 pneumonia were included in the study. Participants' sociodemographic characteristics and initial presentation variables were obtained from hospital records and information forms. Severity of lung involvement (SLI) was obtained from thoracic computed tomography (CT) records. The Hospital Anxiety and Depression Scale (HADS), and Whiteley Index-7 (WI-7) were applied to all participants. Results: HADS-A levels were higher among female patients than among men (p=0.003). Higher WI-7 scores were determined in patients with mild SLI compared to those with moderate-severe SLI (p=0.012). HADS-A scores were higher in patients with primary symptoms of dyspnea, and HADS-D scores were higher in participants with primary symptoms of cough (p=0.026 and p=0.008, respectively). Discussion: Female gender, severity of lung involvement, and symptoms of dyspnea and cough were identified as clinical indicators in terms of mental health evaluation. We think that our results will be a guide for determining the psychiatric support requirements of COVID-19 patients.